Katie Ewer

From Wikipedia, the free encyclopedia
Katie Ewer
Academic background
EducationPhD, Immunology, 2004, Open University
ThesisRelationships between tuberculosis exposure, ex vivo antigen-specific T cell responses, and delayed type hypersensitivity in point-source outbreaks. (2004)
Academic work
InstitutionsUniversity of Oxford

Katie Jane Ewer is a British cellular immunologist. She is an associate professor and Senior Immunologist at the Edward Jenner Institute for Vaccine Research and Nuffield Department of Clinical Medicine.

Early life and education[]

Growing up, Ewer was interested in pursuing a career in biology for she was "fascinated by seemingly endless processes that occur in our cells and organs every second of our lives without us knowing about it."[1] She earned an undergraduate degree in biomedical science, which included a year of microbiology training,[2] before being rejected from medical school.[1] She began working as a biomedical scientist at the microbiology department of the John Radcliffe Hospital in 2000.[3] Having already found a liking for microbiology specializing in infectious diseases, she chose to pursue a PhD on the immunology of tuberculosis (TB).[2] She earned her PhD through Open University as a result of her research with Ajit Lalvani on novel diagnostic tools for tuberculosis.[3]

Career[]

Upon earning her PhD, Ewer joined the UK's Animal and Plant Health Agency where she studied the effectiveness of TB vaccines in cattle and managed the roll-out of interferon-gamma-based diagnosis for bovine TB in the UK herd for the Department for Environment, Food and Rural Affairs.[3] While in this role, she co-published Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study with .[4]

In 2008, Ewer became a Senior Immunologist at Oxford University's Edward Jenner Institute for Vaccine Research.[3] While there, she continued to study the effects of TB on populations and led clinical trials in an effort to discover a vaccine for Ebola.[5] The aim of her research was to define vaccine-induced immunological parameters that correlate with protection from malaria and understand why vaccines do not always work as well as expected.[6] During the COVID-19 pandemic, she led clinical controlled trials in an effort to find a vaccine, which was published in a 2020 study titled Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.[7]

References[]

  1. ^ a b Stokel-Walker, Chris (10 April 2020). "When Will There Be A Coronavirus Vaccine?". esquire.com. Esquire. Retrieved 21 July 2020.
  2. ^ a b Todd, Benjamin (20 November 2013). "Interview with malaria vaccine researcher Katie Ewer". 80000hours.org. Retrieved 21 July 2020.
  3. ^ a b c d "Katie Ewer". conted.ox.ac.uk. Retrieved 21 July 2020.
  4. ^ Susan Liebeschuetz; Sheila Bamber; Katie Ewer; Jonathan Deeks; Ansar A Pathan; Ajit Lalvani (1 December 2004). "Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study". The Lancet. 364 (9452): 2196–2203. doi:10.1016/S0140-6736(04)17592-2. ISSN 0140-6736. PMID 15610806. S2CID 35679204. Wikidata Q46840144.
  5. ^ "Katie Ewer Senior Immunologist: Malaria and Ebola Vaccine Trials". ndm.ox.ac.uk. Retrieved 21 July 2020.
  6. ^ "Katie Ewer ASSOCIATE PROFESSOR". medsci.ox.ac.uk. Retrieved 21 July 2020.
  7. ^ Pedro M Folegatti; Katie J Ewer; Parvinder K Aley; et al. (20 July 2020). "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial". The Lancet. doi:10.1016/S0140-6736(20)31604-4. ISSN 0140-6736. PMC 7445431. PMID 32702298. Wikidata Q97678476.

External links[]

Retrieved from ""